Blood Diseases Market Research Reports & Industry Analysis
Blood Diseases Industry Research & Market Reports
-
The 2025-2030 World Outlook for Blood Cancer Therapeutics
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Anemia Drugs
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Hemophilia Gene Therapies
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Immune Thrombocytopenia
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Hydroxyurea Sickle Cell Disease Treatments
... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More
-
The 2025-2030 World Outlook for Iron Deficiency Anemia Drugs
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Von Willebrand Disease Treatments
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Rare Hemophilia Factors
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Oral Iron Therapy for Iron Deficiency Anemia
... estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. ... Read More
-
The 2025-2030 World Outlook for Plasma Fractionation
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Sickle Cell Anemia Treatments
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Hemophilia Treatments
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Iron Deficiency Anemia Therapies
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Rare Hematology Plasma-Derived Factors
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Haemoglobinopathies
... for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis ... Read More
-
The 2025-2030 World Outlook for Hemoglobinopathies
... for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis ... Read More
-
The 2025-2030 World Outlook for Monocyte Activation Test Kits
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Blood Cancers
... earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a ... Read More
-
The 2025-2030 World Outlook for Bleeding Disorders Treatments
... potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly ... Read More
-
The 2025-2030 World Outlook for Sickle Cell Disease Treatments
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Sickle Cell Disease Hemoglobinopathies
... demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader ... Read More
-
The 2025-2030 World Outlook for Plasma Fractionation of Intravenous Immunoglobulins
... the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow ... Read More
-
Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab, Pegfilgrastim, Trastuzumab, Bevacizumab, and Others), Indication (Auto-Immune Diseases, Blood Disorders, Diabetes, Oncology, Growth Deficiency, Female Infertility, and Others), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Region 2024-2032
... Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Region 2024-2032 The global biosimilar market size reached US$ 21.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 164.5 Billion by 2032, exhibiting ... Read More
-
Warm Autoimmune Hemolytic Anemia (WAIHA) - Market Insight, Epidemiology And Market Forecast - 2034
... of care that involves the prescription of riluzole has been effective in slowing the disease progression, thereby increasing the life span of patients. The most recent development in ALS was the addition of RELYVRIO for ... Read More
-
Warm Autoimmune Hemolytic Anemia (WAIHA) - Epidemiology Forecast - 2034
... common among adults, with a peak incidence between 50 and 70 years. The median age at onset is 52 years. As per the secondary research, the prevalence of wAIHA is 1 per 8,000, and accounts ... Read More
Research Assistance
